JP2021505655A5 - - Google Patents

Download PDF

Info

Publication number
JP2021505655A5
JP2021505655A5 JP2020547315A JP2020547315A JP2021505655A5 JP 2021505655 A5 JP2021505655 A5 JP 2021505655A5 JP 2020547315 A JP2020547315 A JP 2020547315A JP 2020547315 A JP2020547315 A JP 2020547315A JP 2021505655 A5 JP2021505655 A5 JP 2021505655A5
Authority
JP
Japan
Prior art keywords
bischoline
tetrathiomolybdate
patient
pharmaceutical composition
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020547315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505655A (ja
JP7852200B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/083551 external-priority patent/WO2019110619A1/en
Publication of JP2021505655A publication Critical patent/JP2021505655A/ja
Publication of JP2021505655A5 publication Critical patent/JP2021505655A5/ja
Priority to JP2023038205A priority Critical patent/JP2023075247A/ja
Priority to JP2025010250A priority patent/JP2025066802A/ja
Application granted granted Critical
Publication of JP7852200B2 publication Critical patent/JP7852200B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020547315A 2017-12-04 2018-12-04 ウィルソン病を治療するためのビスコリンテトラチオモリブデート Active JP7852200B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023038205A JP2023075247A (ja) 2017-12-04 2023-03-13 ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2025010250A JP2025066802A (ja) 2017-12-04 2025-01-24 ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762594184P 2017-12-04 2017-12-04
US62/594,184 2017-12-04
US201862646553P 2018-03-22 2018-03-22
US62/646,553 2018-03-22
US201862655568P 2018-04-10 2018-04-10
US62/655,568 2018-04-10
US201862669095P 2018-05-09 2018-05-09
US62/669,095 2018-05-09
US201862741313P 2018-10-04 2018-10-04
US62/741,313 2018-10-04
US201862750595P 2018-10-25 2018-10-25
US62/750,595 2018-10-25
PCT/EP2018/083551 WO2019110619A1 (en) 2017-12-04 2018-12-04 Bis-choline tetrathiomolybdate for treating wilson disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023038205A Division JP2023075247A (ja) 2017-12-04 2023-03-13 ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Publications (3)

Publication Number Publication Date
JP2021505655A JP2021505655A (ja) 2021-02-18
JP2021505655A5 true JP2021505655A5 (https=) 2022-01-11
JP7852200B2 JP7852200B2 (ja) 2026-04-28

Family

ID=64661349

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020547315A Active JP7852200B2 (ja) 2017-12-04 2018-12-04 ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2023038205A Pending JP2023075247A (ja) 2017-12-04 2023-03-13 ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2025010250A Pending JP2025066802A (ja) 2017-12-04 2025-01-24 ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023038205A Pending JP2023075247A (ja) 2017-12-04 2023-03-13 ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2025010250A Pending JP2025066802A (ja) 2017-12-04 2025-01-24 ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Country Status (16)

Country Link
US (3) US11510944B2 (https=)
EP (3) EP4523745A3 (https=)
JP (3) JP7852200B2 (https=)
KR (1) KR102803161B1 (https=)
AU (1) AU2018379255B2 (https=)
BR (1) BR112020011055A2 (https=)
DK (2) DK4029498T3 (https=)
ES (2) ES3026756T3 (https=)
FI (1) FI4029498T3 (https=)
HU (2) HUE071155T2 (https=)
IL (1) IL275115B2 (https=)
MX (1) MX2020006284A (https=)
PL (2) PL4029498T3 (https=)
PT (2) PT4029498T (https=)
SI (2) SI4029498T1 (https=)
WO (1) WO2019110619A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
MX2020006284A (es) * 2017-12-04 2021-04-12 Alexion Pharma Int Operations Unlimited Company Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
WO2019154876A1 (en) 2018-02-06 2019-08-15 Wilson Therapeutics Ab Crystalline particles of bis-choline tetrathiomolybdate
US20220387370A1 (en) 2019-11-21 2022-12-08 Alexion Pharmaceuticals, Inc. Methods of reducing neurological damage in wilson disease patients
CN116601173A (zh) * 2020-09-11 2023-08-15 阿雷克森制药公司 抗铜蓝蛋白抗体及其用途
EP4243806A1 (en) * 2020-11-13 2023-09-20 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
JP2024505229A (ja) * 2021-01-31 2024-02-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 銅代謝関連疾患又は障害を治療するための新規製剤
WO2023023199A1 (en) 2021-08-17 2023-02-23 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
WO2024162974A1 (en) 2023-01-30 2024-08-08 Alexion Pharmaceuticals, Inc. Tetrathiomolybdic acid for use in treating copper metabolism-associated diseases or disorders (wilson disease)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189865B2 (en) 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
GEP20074270B (en) * 2002-07-23 2007-12-25 Univ Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
CA2675230A1 (en) 2006-01-10 2008-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
MX2020006284A (es) 2017-12-04 2021-04-12 Alexion Pharma Int Operations Unlimited Company Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
WO2019154876A1 (en) 2018-02-06 2019-08-15 Wilson Therapeutics Ab Crystalline particles of bis-choline tetrathiomolybdate

Similar Documents

Publication Publication Date Title
JP2021505655A5 (https=)
JP7424676B2 (ja) マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤
AU746887B2 (en) Treatment of persistent pain
US20180235934A1 (en) Noradrenergic drug treatment of obstructive sleep apnea
JP2017537089A5 (https=)
CN102056603A (zh) 决奈达隆用于预防持续性心房纤颤
JP2016516016A5 (https=)
AU2013237881B2 (en) Dosage forms of halofuginone and methods of use
AU2025203339A1 (en) Therapeutic Uses of Tirzepatide
CN107823195A (zh) R‑氯胺酮在抑郁症急性期治疗中的应用
JP2020536121A5 (https=)
CN110974828B (zh) 化合物Axitinib在制备治疗脑血管疾病的药物中的应用及其药物组合物
JP2004525940A (ja) 火照りの処置のためのデュロキセチン
BR112020007817A2 (pt) método de uso e composições contendo dulaglutido
KR20110026421A (ko) 심장율동전환의 예방을 위한 드로네다론
CN109646438A (zh) 去甲乌药碱或其盐酸盐在制备治疗鼻炎药物中的应用
EP2184284B1 (en) Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
CN107205944A (zh) 用于纠正衰弱和/或慢性疲劳综合征的症状或治疗衰弱和/或慢性疲劳综合征的药物组合物
US20240277670A1 (en) Safe use of mmp-12 inhibitor
JP6028983B2 (ja) ビダラビンによる心房細動治療
CN102225083B (zh) 一种治疗高血压、高血脂的药物组合物及其应用
WO2016109462A1 (en) Pharmaceutical composition and method for treating age-related macular degeneration
CN102488676B (zh) 替普瑞酮在制备预防和/或治疗抑郁症药物中的应用
Tab enoxacin (C) 400 mg x 1 dose
WO2003020274A1 (en) Treatment of atopic dermatitis